Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Veracyte (VCYT) EBITDA Margin (2016 - 2026)

Veracyte's EBITDA Margin history spans 14 years, with the latest figure at 26.45% for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 2293.0% to 26.45% in Q4 2025 year-over-year; TTM through Dec 2025 was 11.17%, a 755.0% increase, with the full-year FY2025 number at 11.17%, up 755.0% from a year prior.
  • EBITDA Margin hit 26.45% in Q4 2025 for Veracyte, up from 17.4% in the prior quarter.
  • Over the last five years, EBITDA Margin for VCYT hit a ceiling of 26.45% in Q4 2025 and a floor of 114.07% in Q1 2021.
  • Historically, EBITDA Margin has averaged 13.54% across 5 years, with a median of 10.83% in 2023.
  • Biggest five-year swings in EBITDA Margin: plummeted -7643bps in 2021 and later surged 9158bps in 2022.
  • Tracing VCYT's EBITDA Margin over 5 years: stood at 18.32% in 2021, then soared by 63bps to 6.75% in 2022, then plummeted by -436bps to 36.16% in 2023, then skyrocketed by 110bps to 3.52% in 2024, then surged by 652bps to 26.45% in 2025.
  • Business Quant data shows EBITDA Margin for VCYT at 26.45% in Q4 2025, 17.4% in Q3 2025, and 4.05% in Q2 2025.